LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells

Cancer Letters

Volumn 364, Issue 1, 2015, Pages 17-24

  Zienert, Elisa ^a   Eke, Iris ^a   Aust, Daniela ^a   Cordes, Nils ^a,b,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Extracellular matrix; FHL2; Pancreatic cancer; Radioresistance

Indexed keywords

FOUR AND HALF LIM DOMAIN PROTEIN 2; LIM PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; UNCLASSIFIED DRUG; FHL2 PROTEIN, HUMAN; LIM HOMEODOMAIN PROTEIN; MUSCLE PROTEIN; PROTEIN KINASE; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; CARCINOMA, PANCREATIC DUCTAL; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RADIATION DOSE; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; LIM-HOMEODOMAIN PROTEINS; MUSCLE PROTEINS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; RADIATION TOLERANCE; TRANSCRIPTION FACTORS;

EID: 84929654778     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.019     Document Type: Article

References (50)

1. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Gut 2007, 56:1134-1152.
2. O'Reilly E.M. Adjuvant therapy for pancreas adenocarcinoma. J. Surg. Oncol 2013, 107:78-85.
3. Wang F., Kumar P. The role of radiotherapy in management of pancreatic cancer. J. Gastrointest. Oncol 2011, 2:157-167.
4. Grzesiak J.J., Ho J.C., Moossa A.R., Bouvet M. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas 2007, 35:293-301.
5. Cordes N., Meineke V. Cell adhesion-mediated radioresistance (CAM-RR): extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther. Onkol 2003, 179:337-344.
6. Hehlgans S., Eke I., Storch K., Haase M., Baretton G.B., Cordes N. Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother. Oncol 2009, 92:362-370.
7. Walsh N., Clynes M., Crown J., O'Donovan N. Alterations in integrin expression modulates invasion of pancreatic cancer cells. J. Exp. Clin. Cancer Res 2009, 28:140.
8. Legate K.R., Montanez E., Kudlacek O., Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat. Rev. Mol. Cell Biol 2006, 7:20-31.
9. Hehlgans S., Haase M., Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 2007, 1775:163-180.
10. Winograd-Katz S.E., Fassler R., Geiger B., Legate K.R. The integrin adhesome: from genes and proteins to human disease. Nat. Rev. Mol. Cell Biol 2014, 15:273-288.
11. Cordes N. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res 2004, 64:5683-5692.
12. Eke I., Koch U., Hehlgans S., Sandfort V., Stanchi F., Zips D., et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J. Clin. Invest 2010, 120:2516-2527.
13. Johannessen M., Moller S., Hansen T., Moens U., Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci 2006, 63:268-284.
14. Kadrmas J.L., Beckerle M.C. The LIM domain: from the cytoskeleton to the nucleus. Nat. Rev. Mol. Cell Biol 2004, 5:920-931.
15. Wixler V., Geerts D., Laplantine E., Westhoff D., Smyth N., Aumailley M., et al. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J. Biol. Chem 2000, 275:33669-33678.
16. Genini M., Schwalbe P., Scholl F.A., Remppis A., Mattei M.G., Schafer B.W. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol 1997, 16:433-442.
17. Ding L., Wang Z., Yan J., Yang X., Liu A., Qiu W., et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J. Clin. Invest 2009, 119:349-361.
18. Gabriel B., Fischer D.C., Orlowska-Volk M., zur Hausen A., Schule R., Muller J.M., et al. Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study. J. Soc. Gynecol. Investig 2006, 13:69-75.
19. Gabriel B., Mildenberger S., Weisser C.W., Metzger E., Gitsch G., Schule R., et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004, 24:921-927.
20. Li M., Wang J., Ng S.S., Chan C.Y., Chen A.C., Xia H.P., et al. The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia 2008, 56:1328-1338.
21. Wang J., Yang Y., Xia H.H., Gu Q., Lin M.C., Jiang B., et al. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007, 132:1066-1076.
22. Yan J., Zhu J., Zhong H., Lu Q., Huang C., Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett 2003, 553:183-189.
23. Purcell N.H., Darwis D., Bueno O.F., Muller J.M., Schule R., Molkentin J.D. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol. Cell. Biol 2004, 24:1081-1095.
24. Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005, 24:1021-1032.
25. Neuzillet C., Hammel P., Tijeras-Raballand A., Couvelard A., Raymond E. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013, 32:147-162.
26. Kang C.M., Park K.P., Song J.E., Jeoung D.I., Cho C.K., Kim T.H., et al. Possible biomarkers for ionizing radiation exposure in human peripheral blood lymphocytes. Radiat. Res 2003, 159:312-319.
27. Paul S., Amundson S.A. Gene expression signatures of radiation exposure in peripheral white blood cells of smokers and non-smokers. Int. J. Radiat. Biol 2011, 87:791-801.
28. Eke I., Storch K., Krause M., Cordes N. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res 2013, 73:5869-5879.
29. Haase M., Gmach C.C., Eke I., Hehlgans S., Baretton G.B., Cordes N. Expression of integrin-linked kinase is increased in differentiated cells. J. Histochem. Cytochem 2008, 56:819-829.
30. Storch K., Eke I., Borgmann K., Krause M., Richter C., Becker K., et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010, 70:3925-3934.
31. Eke I., Deuse Y., Hehlgans S., Gurtner K., Krause M., Baumann M., et al. beta(1)Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J. Clin. Invest 2012, 122:1529-1540.
32. Sandfort V., Eke I., Cordes N. The role of the focal adhesion protein PINCH1 for the radiosensitivity of adhesion and suspension cell cultures. PLoS ONE 2010, 5.
33. Eke I., Storch K., Kastner I., Vehlow A., Faethe C., Mueller-Klieser W., et al. Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int. J. Radiat. Oncol. Biol. Phys 2012, 84:e515-e523.
34. Segara D., Biankin A.V., Kench J.G., Langusch C.C., Dawson A.C., Skalicky D.A., et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin. Cancer Res 2005, 11:3587-3596.
35. Badea L., Herlea V., Dima S.O., Dumitrascu T., Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008, 55:2016-2027.
36. Nones K., Waddell N., Song S., Patch A.M., Miller D., Johns A., et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int. J. Cancer 2014, 135:1110-1118.
37. Preis M., Korc M. Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol. Ther 2010, 9:754-763.
38. Nouet Y., Dahan J., Labalette C., Levillayer F., Julien B., Jouvion G., et al. The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis. J. Hepatol 2012, 57:1029-1036.
39. Qian Z., Mao L., Fernald A.A., Yu H., Luo R., Jiang Y., et al. Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo. Leukemia 2009, 23:1650-1657.
40. Verset L., Tommelein J., Moles Lopez X., Decaestecker C., Mareel M., Bracke M., et al. Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer. Br. J. Cancer 2013, 109:114-120.
41. Zhang W., Wang J., Zou B., Sardet C., Li J., Lam C.S., et al. Four and a half LIM protein 2 (FHL2) negatively regulates the transcription of E-cadherin through interaction with Snail1. Eur. J. Cancer 2011, 47:121-130.
42. Brun J., Dieudonne F.X., Marty C., Muller J., Schule R., Patino-Garcia A., et al. FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS ONE 2013, 8:e55034.
43. Martin B.T., Kleiber K., Wixler V., Raab M., Zimmer B., Kaufmann M., et al. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 2007, 6:1779-1788.
44. Kleiber K., Strebhardt K., Martin B.T. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 2007, 27:55-61.
45. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol 2009, 23:572-583.
46. McGrath M.J., Binge L.C., Sriratana A., Wang H., Robinson P.A., Pook D., et al. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. Cancer Res 2013, 73:5066-5079.
47. Han W., Wu Z., Zhao Y., Meng Y., Si Y., Yang J., et al. FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells. Nucleic Acids Res 2009, 37:3996-4009.
48. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
49. Chaves-Perez A., Mack B., Maetzel D., Kremling H., Eggert C., Harreus U., et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2013, 32:641-650.
50. Labalette C., Nouet Y., Levillayer F., Armengol C., Renard C.A., Soubigou G., et al. The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways. PLoS ONE 2008, 3:e3761.